Cargando…
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645499/ http://dx.doi.org/10.1186/2051-1426-3-S2-P83 |
| _version_ | 1782400826413678592 |
|---|---|
| author | Powles, Thomas Nickles, Dorothee Van Allen, Eliezer Chappey, Colombe Zou, Wei Kowanetz, Marcin Kadel, Edward Denker, Mitchell Boyd, Zachary Vogelzang, Nicholas Kim, Joseph Bellmunt, Joaquim Loriot, Yohann Drake, Charles G O'Hear, Carol Fasso, Marcella Hegde, Priti Mariathasan, Sanjeev |
| author_facet | Powles, Thomas Nickles, Dorothee Van Allen, Eliezer Chappey, Colombe Zou, Wei Kowanetz, Marcin Kadel, Edward Denker, Mitchell Boyd, Zachary Vogelzang, Nicholas Kim, Joseph Bellmunt, Joaquim Loriot, Yohann Drake, Charles G O'Hear, Carol Fasso, Marcella Hegde, Priti Mariathasan, Sanjeev |
| author_sort | Powles, Thomas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645499 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46454992015-11-20 Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) Powles, Thomas Nickles, Dorothee Van Allen, Eliezer Chappey, Colombe Zou, Wei Kowanetz, Marcin Kadel, Edward Denker, Mitchell Boyd, Zachary Vogelzang, Nicholas Kim, Joseph Bellmunt, Joaquim Loriot, Yohann Drake, Charles G O'Hear, Carol Fasso, Marcella Hegde, Priti Mariathasan, Sanjeev J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645499/ http://dx.doi.org/10.1186/2051-1426-3-S2-P83 Text en Copyright © 2015 Powles et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Powles, Thomas Nickles, Dorothee Van Allen, Eliezer Chappey, Colombe Zou, Wei Kowanetz, Marcin Kadel, Edward Denker, Mitchell Boyd, Zachary Vogelzang, Nicholas Kim, Joseph Bellmunt, Joaquim Loriot, Yohann Drake, Charles G O'Hear, Carol Fasso, Marcella Hegde, Priti Mariathasan, Sanjeev Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) |
| title | Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) |
| title_full | Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) |
| title_fullStr | Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) |
| title_full_unstemmed | Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) |
| title_short | Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) |
| title_sort | immune biomarkers associated with clinical benefit from atezolizumab (mpdl3280a; anti-pd-l1) in advanced urothelial bladder cancer (ubc) |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645499/ http://dx.doi.org/10.1186/2051-1426-3-S2-P83 |
| work_keys_str_mv | AT powlesthomas immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT nicklesdorothee immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT vanalleneliezer immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT chappeycolombe immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT zouwei immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT kowanetzmarcin immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT kadeledward immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT denkermitchell immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT boydzachary immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT vogelzangnicholas immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT kimjoseph immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT bellmuntjoaquim immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT loriotyohann immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT drakecharlesg immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT ohearcarol immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT fassomarcella immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT hegdepriti immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc AT mariathasansanjeev immunebiomarkersassociatedwithclinicalbenefitfromatezolizumabmpdl3280aantipdl1inadvancedurothelialbladdercancerubc |